Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Sanofi Goes Hostile | Main | Chemical Biology: Plastic Antibodies? »

October 4, 2010

Spamming For Site Shutdowns. Sheesh.

Email This Entry

Posted by Derek

Well, this doesn't look encouraging. As part of its restructuring after buying Schering-Plough, Merck announced some time back that it's shedding the former Organon sites in Newhouse in Scotland and Schaijk in the Netherlands.

How's that going? Well, a correspondent forwarded me an unsolicited email he just received from "Partner International", the company hired by Merck to help divest these sites. And apparently Partner's strategy includes. . .spamming people with a one-page brochure touting this "Time Sensitive Acquisition Opportunity" for these "world class research opportunities".

My correspondent, regrettably, finds himself a bit short this month and unable to purchase either of these research sites. Perhaps someone else will idly browse their inbox and take Partner International up on this time-sensitive offer. If the message gets through the spam filter, that is.

Comments (9) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. Petros on October 4, 2010 9:40 AM writes...

The Oss site, but not the R&D effort there, has been saved for now.

I was there at a meeting the other week and heard on the Tuesday that Abbott was closing the Solvay sites in Europe!

Astellas was supposed to be telling the UK group of OSI their fate last week too

Permalink to Comment

2. Anon on October 4, 2010 9:45 AM writes...

With consolidations, downsizing, moving work to India, China, it seems inevitable that there will be excess Pharma site capacities in Europe & US. Shire can only absorb so much....

Permalink to Comment

3. JT on October 4, 2010 11:40 AM writes...

How much are they selling for? If it's in the same price range as the other products (VIIAAGRAA/KIALIS) I get spammed with, we can probably work out a deal!

Permalink to Comment

4. Will on October 4, 2010 1:31 PM writes...

As soon as I complete my pending transactions with a Nigerian widow needing assistance accessing her late husband's vast fortune currently sitting in a Lagos bank I should have plenty of funding to apply to the purchase

Permalink to Comment

5. John on October 4, 2010 2:47 PM writes...

Surpisingly to many, this type of email campaign is a common part of these type of divestiture campaigns. If your friend is not in finance or corporate development, it is likely that his name is similar to someone who is. I've participated in some of these campaigns, and the hard part is usually in getting accurate email addresses. The senior financial and corporate development positions at these companies often turnover every few years and commerical databases are usually hopelessly out of date. Needless to say, most companies don't put the email addresses of their senior execs on their websites.

Permalink to Comment

6. Sayuri on October 5, 2010 4:26 AM writes...

to Petros:

Yesterday our CEO Astellas Mr. Nogimori was here at Astellas plant in Meppel (NL) for a visit.
During his presentation about future global strategies he was really pleased to report the OSI takeover. He was really pleased that Astellas succeeded in adding to our knowledge the OSI strong oncology expertise. When we asked about the future of OSI as company hementioned that now we have 500 Astellas colleagues more: OSI's people.
I hope this was including the people in UK.

Permalink to Comment

7. xfin31 on October 5, 2010 7:05 AM writes...

Well, it's to be seen whether Merck make a better fist of it than in the past. Terlings Park in the UK is still lying empty 5 years after the shutdown. Go figure how that affected the cost/benefit calculations!

Permalink to Comment

8. Anonymous on October 5, 2010 8:42 AM writes...

Well, why don't they think of putting large department stores in ex-R&D sites and employ the ex-R&D-staff as cooks, waiters, cleaners, mechanics, storekeepers, cashiers, ticket-sellers, etc....

Permalink to Comment

9. Chris on October 5, 2010 10:13 AM writes...

I got one of these too. I didn't realize I was such a captain of industry. Doubt I have the room on my AMEX to buy it, sadly.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All